Braveheart Bio, Inc. (BRVE) income statement
BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$20.39+1.12 (+5.81%)
Close on Nov 20, 2026Market cap $1.84BP/E –Yield –
Braveheart Bio, Inc. financial ratios
See a number that looks wrong?